Mina Sooch, MBA Chief Executive Officer
Ms. Sooch is a co-founder of Ocuphire and has served as Chief Executive Officer. With over 23 years of pharma/biotech experience as CEO, entrepreneur, venture capitalist, and strategist, Ms. Sooch has successfully raised hundreds of millions of dollars for over 10 biotechnology, medical device, and pharmaceutical companies, including two successful IPOs. Prior to Ocuphire, Ms. Sooch was a co-founder and CEO of Gemphire Therapeutics, a publicly-traded, clinical-stage cardiovascular company. Ms. Sooch’s leadership was instrumental in the company’s successful IPO in 2016. From July 2012 to May 2014, Ms. Sooch was a co-founder and CEO of ProNAi Therapeutics, a public, clinical-stage oncology company, and a member of the board of directors from its founding in 2004 through May 2014. At ProNai, Ms. Sooch guided the company through several important milestones, including a podium presentation at ASH 2013 for phase 2 cancer response rates on lead drug candidate, and raised $60M from over 10 institutional investors setting up the IPO. Ms. Sooch also co-founded Apjohn Ventures Fund, a venture capital firm that invested primarily in early-stage life sciences companies and has served as its Managing Partner since its founding in 2003. Earlier in her career from 1993-2000, Ms. Sooch served as global account manager at Monitor Group, a top-tier global strategy consulting firm based in Boston. Ms. Sooch worked on the multi-billion Pharmacia & Upjohn merger in 1995 and later co-led the launch of the Corporate Finance group specializing in M&A, valuations, and merger integration. Ms. Sooch has served on the boards of over 10 private, public, and nonprofit firms, and has been the recipient of numerous awards, including being named one of the Deal Makers of the year in 2016 by Crain’s Detroit Business. Ms. Sooch received an M.B.A. from Harvard Business School and a B.S. summa cum laude in Chemical Engineering from Wayne State University in Michigan.